Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tipifarnib in Treating Patients With Myeloproliferative Disorders

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00005846
First received: June 2, 2000
Last updated: June 4, 2011
Last verified: July 2005
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given
Publications:
Gotlib J, Loh M, Vattikuti S, et al.: Phase I/II study of tipifarnib (ZARNESTRA, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders(MPDs): preliminary results. [Abstract] Blood 100 (Suppl 1): 798a, 2002.